PURPOSE: The clinical effect of @entity4392 on QT intervals was prospectively studied. SUBJECTS: Consecutive adult @entity1 were recruited in whom @entity4392 was indicated for @entity354 , @entity2275 , duodenal @entity1066 , @entity6 or chronic constipation refractory to laxatives. Exclusion criteria included disorders and medications affecting cardiac conduction, electrolyte homeostasis, drug clearance and membrane stability. METHODS: Seventy-five @entity1 were included and followed at 1 to 2 week intervals. @entity1 took @entity4392 5 mg thrice daily for 1 to 4 weeks (lower dose stage), followed by 10 mg thrice daily for another 1 to 4 weeks (higher dose stage). Twelve-lead ECGs were performed before commencing @entity4392 (group B), at completion of the lower dose stage (group L) and at completion of the higher dose stage (group H). RESULTS: No @entity1 experienced @entity1163 or @entity1163 . Seventeen @entity1 failing to comply, and 7 complaining of abdominal discomfort or @entity294 were excluded, leaving 51 @entity1 . Group H's corrected QT interval (QTc) was longer than group B's by 13+/-15 ms (P<0.001), and longer than group L's by 7+/-11 ms (P<0.001). Group L's QTc was longer than group B's by 7+/-21 ms (P<0.05). QT dispersion did not differ significantly among groups. Neither @entity1166 nor @entity1165 were noted in Holter monitoring of 33 @entity1 during the higher dose stage. CONCLUSION: @entity4392 dose-dependently prolongs the QT interval. Further study is needed to examine the arrhythmogenicity of @entity4392 in higher doses and for longer durations.

QT interval effects of XXXX in the clinical setting.

@entity4392 :: ('MESH:D020117', 'Chemical') :: ['cisapride'] @entity1 :: ('9606', 'Species') :: ['participants', 'Patients', 'patients'] @entity1165 :: ('MESH:D017180', 'Disease') :: ['ventricular tachycardia'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic gastroparesis'] @entity1166 :: ('MESH:D016171', 'Disease') :: ['torsade de pointe'] @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity1163 :: ('MESH:D013575', 'Disease') :: ['syncope', 'presyncope'] @entity354 :: ('MESH:D005764', 'Disease') :: ['gastroesophogeal reflux'] @entity2275 :: ('MESH:D013276', 'Disease') :: ['gastric ulcer']
@entity4392 :: (MESH:D020117,Chemical) :: ['cisapride']
